Randomized open-label phase III multicenter trial comparing TAXOL®/doxorubicin (AT) versus 5-fluorouracil/doxorubicin and cyclophosphamide (FAC) as a first line treatment for patients with metastatic breast cancer
- 30 September 1999
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 35, S314-314
- https://doi.org/10.1016/s0959-8049(99)81676-1
Abstract
No abstract availableThis publication has 0 references indexed in Scilit: